Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | GALR3 | O60755 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.48 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.48 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2214414 | 1.00 | L3MBTL1 (0.54) | L3MBTL1POLBMEN1KMT2AGALR3 | |
| SCHEMBL3739385 | 1.00 | L3MBTL1 (0.54) | L3MBTL1POLBMEN1KMT2AGALR3 | |
| SCHEMBL12435714 | 1.00 | L3MBTL1 (0.54) | L3MBTL1POLBMEN1KMT2AGALR3 | |
| SCHEMBL2214406 | 1.00 | L3MBTL1 (0.54) | L3MBTL1POLBMEN1KMT2AGALR3 | |
| SCHEMBL2220842 | 1.00 | L3MBTL1 (0.54) | L3MBTL1POLBMEN1KMT2AGALR3 | |
| SCHEMBL12435712 | 1.00 | L3MBTL1 (0.54) | L3MBTL1POLBMEN1KMT2AGALR3 | |
| SCHEMBL4124880 | 0.95 | MEN1 (0.57) | L3MBTL1POLBMEN1KMT2AGALR3 | |
| Phosphoric Acid SCHEMBL28774984 | 0.94 | MEN1 (0.49) | L3MBTL1POLBMEN1KMT2AGALR3 | |
| Phosphoric Acid SCHEMBL28774993 | 0.94 | MEN1 (0.49) | L3MBTL1POLBMEN1KMT2AGALR3 | |
| SCHEMBL9061218 | 0.94 | POLB (0.58) | L3MBTL1POLBMEN1KMT2AGALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9428448-B2 | Compounds and methods of treating obesity | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-10-16 | — | — | US | disclosed |
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW (IL) | 2011-07-21 | — | — | US | disclosed |
| EP-2262763-A2 | COMPOUNDS AND METHODS OF TREATING OBESITY | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009109973-A2 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2009-09-11 | — | — | WO | disclosed |
| EP-0421441-B1 | Pantothenic acid derivatives | FUJIREBIO KK (JP) | 1995-01-25 | — | — | EP | disclosed |
| US-5120738-A | Cardiovascular disorders | FUJIREBIO INC. (JP) | 1992-06-09 | — | — | US | disclosed |
| EP-0421441-A2 | Pantothenic acid derivatives | FUJIREBIO INC. (JP) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | FABP4, LIPC, GPR119 | L3MBTL1 4099/4885POLB 2957/4885MEN1 4525/4885 |
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | GPR119, FABP4, LIPC | L3MBTL1 4450/4885POLB 3689/4885MEN1 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.